» Articles » PMID: 33247481

Characterization of Wound Microbes in Epidermolysis Bullosa: Results from the Epidermolysis Bullosa Clinical Characterization and Outcomes Database

Abstract

Background/objectives: Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected with bacteria. A subset of EB patients are at risk for squamous cell carcinoma, and bacterial-host interactions have been considered in this risk. The EB Clinical Characterization and Outcomes Database serves as a repository of information from EB patients at multiple centers in the United States and Canada. Access to this resource enabled broad-scale analysis of wound cultures.

Methods: A retrospective analysis of 739 wound cultures from 158 patients from 13 centers between 2001 and 2018.

Results: Of 152 patients with a positive culture, Staphylococcus aureus (SA) was recovered from 131 patients (86%), Pseudomonas aeruginosa (PA) from 56 (37%), and Streptococcus pyogenes (GAS) from 34 (22%). Sixty-eight percent of patients had cultures positive for methicillin-sensitive SA, and 47%, methicillin-resistant SA (18 patients had cultures that grew both methicillin-susceptible and methicillin-resistant SA at different points in time). Of 15 patients with SA-positive cultures with recorded mupirocin susceptibility testing, 11 had mupirocin-susceptible SA and 6 patients mupirocin-resistant SA (2 patients grew both mupirocin-susceptible and mupirocin-resistant SA). SCC was reported in 23 patients in the entire database, of whom 10 had documented wound cultures positive for SA, PA, and Proteus species in 90%, 50%, and 20% of cases, respectively.

Conclusions: SA and PA were the most commonly isolated bacteria from wounds. Methicillin resistance and mupirocin resistance were reported in 47% and 40% of patients tested, respectively, highlighting the importance of ongoing antimicrobial strategies to limit antibiotic resistance.

Citing Articles

Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study.

Quintana-Castanedo L, Sanchez-Ramon S, Maseda R, Illera N, Perez-Conde I, Molero-Luis M Exp Dermatol. 2024; 33(8):e15146.

PMID: 39075828 PMC: 11605501. DOI: 10.1111/exd.15146.


Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa.

Syafarina I, Mazaya M, Indrawati A, Akbar S, Sukowati C, Sadikin R Curr Drug Targets. 2024; 25(6):404-415.

PMID: 38566380 DOI: 10.2174/0113894501290512240327091531.


Epidermolysis bullosa in a mother-infant dyad.

Prashanth R, Kamble P, Kumari A, Haribalakrishna A, Mahajan S Oxf Med Case Reports. 2023; 2023(11):omad124.

PMID: 38033404 PMC: 10686001. DOI: 10.1093/omcr/omad124.


Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa.

Scollan M, Levin L, Lucky A, Hook K, Peoples K, Bruckner A Pediatr Dermatol. 2023; 40(5):863-865.

PMID: 37364926 PMC: 10543531. DOI: 10.1111/pde.15383.


Staphylococcal Infections and Neonatal Skin: Data from Literature and Suggestions for the Clinical Management from Four Challenging Patients.

De Rose D, Pugnaloni F, Martini L, Bersani I, Ronchetti M, Diociaiuti A Antibiotics (Basel). 2023; 12(4).

PMID: 37106994 PMC: 10135205. DOI: 10.3390/antibiotics12040632.


References
1.
van der Kooi-Pol M, Duipmans J, Jonkman M, van Dijl J . Host-pathogen interactions in epidermolysis bullosa patients colonized with Staphylococcus aureus. Int J Med Microbiol. 2014; 304(2):195-203. DOI: 10.1016/j.ijmm.2013.11.012. View

2.
Antonov N, Garzon M, Morel K, Whittier S, Planet P, Lauren C . High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population. Antimicrob Agents Chemother. 2015; 59(6):3350-6. PMC: 4432188. DOI: 10.1128/AAC.00079-15. View

3.
Hoste E, Arwert E, Lal R, South A, Salas-Alanis J, Murrell D . Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun. 2015; 6:5932. PMC: 4338544. DOI: 10.1038/ncomms6932. View

4.
Hetem D, Bonten M . Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect. 2013; 85(4):249-56. DOI: 10.1016/j.jhin.2013.09.006. View

5.
Shayegan L, Levin L, Galligan E, Lucky A, Bruckner A, Pope E . Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database. Pediatr Dermatol. 2020; 37(2):326-332. DOI: 10.1111/pde.14102. View